Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state

• Main Authors: Philipp Schommers (Author), Anna Thurau (Author), Insa Bultmann-Mellin (Author), Maria Guschlbauer (Author), Andreas R. Klatt (Author), Jan Rozman (Author), Martin Klingenspor (Author), Martin Hrabe de Angelis (Author), Jens Alber (Author), Dirk Gründemann (Author), Anja Sterner-Kock (Author), Rudolf J. Wiesner (Author)
• Format: Book
• Published: Elsevier, 2017-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Metformin, the first line drug for treatment of type 2 diabetes, suppresses hepatic gluconeogenesis and reduces body weight in patients, the latter by an unknown mechanism. Methods: Mice on a high fat diet were continuously fed metformin in a therapeutically relevant dose, mimicking a ret...